PharmaLex Group Completes Merger with BioStat Solutions

Published on: 
In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter 10-07-2020, Volume 15, Issue 10

The merged company can offer enhanced statistical and data analytics services.

PharmaLex Group, a pharma, biotech and medical device industries provider, completed its merger with BioStat Solutions (BSSI), a data analytics company. The merged company will enhance service offerings in data analytics. BSSI strengths lay in analytical solutions that can resolve data complexities and expertise in high-dimensional data, including real-world evidence and -omics data, according to a Sept. 29, 2020 press release.

Under the terms of the merger, Lin Li, the senior director of Scientific Operations at BSSI will take over management of BSSI, Ron Bromley will step down from his position as CEO of BSSI, and Ena Bromley will continue to hold her position as non-executive director and principal consultant at BSSI.

“PharmaLex is a leading service provider in the pharma, biotech, and medical device industries,” said Li in the press release. “It is an exciting challenge to support them in developing their statistical solutions services and I look forward to leading the US team.”


“BSSI has had a focus on translational medicine and bioinformatics,” added Dr. Thomas Dobmeyer, CEO, PharmaLex, in the press release. “Their service portfolio complements nicely with our existing statistical solutions which focuses more on Bayesian statistics and will allow us to further enhance the services we are able to offer our clients—within the growing biomarker and bioinformatics market, which are both expected to grow with >13% per annum.”

Source: PharmaLex